Standout Papers

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthriti... 2012 2026 2016 2021 422
  1. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease (2012)
    Gerd R Burmester, Remo Panaccione et al. Annals of the Rheumatic Diseases

Immediate Impact

2 by Nobel laureates 12 from Science/Nature 60 standout
Sub-graph 1 of 23

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Principles and therapeutic applications of adaptive immunity
2024 Standout
2 intermediate papers

Works of M. McIlraith being referenced

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
2012 Standout
Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions
1997

Author Peers

Author Last Decade Papers Cites
M. McIlraith 217 358 128 17 653
Derek Brown 153 295 107 12 630
Martin Birkhofer 122 364 138 20 793
J Sánchez-Román 351 313 77 33 808
Edward Flynn 357 441 222 24 821
S Arienti 427 378 56 14 713
Cristina Tommasi 317 263 55 16 706
S. Menon 497 235 110 15 605
E. J. Davies 261 389 52 18 807
T Radaszkiewicz 136 356 191 27 642
M. Schiff 414 172 197 10 637

All Works

Loading papers...

Rankless by CCL
2026